Letrozole Zentiva Pharma

Letrozole, the active ingredient in Letrozole Zentiva Pharma, is an aromatase inhibitor presented as a tablet for oral use. It belongs to the antineoplastic hormone therapy class and is indicated for hormone receptor‑positive breast cancer in postmenopausal women.

GNH USA supplies Letrozole Zentiva Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Letrozole acts on estrogen‑dependent breast cancer pathways and is used in several clinical settings. - Adjuvant treatment of early‑stage hormone receptor‑positive breast cancer: reduces risk of recurrence after surgery. - Metastatic hormone receptor‑positive breast cancer: slows disease progression in postmenopausal women. - Neoadjuvant therapy for locally advanced breast cancer: shrinks tumor size before surgery.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Hot flashes - Joint and muscle pain - Fatigue - Nausea

Serious or Rare Side Effects: - Severe liver injury - Bone fracture due to decreased bone mineral density - Allergic reactions such as rash, angioedema, or anaphylaxis

Patients should be monitored for specific safety concerns before and during therapy. - Bone health monitoring: assess bone mineral density and consider calcium/vitamin D supplementation. - Liver function assessment: perform baseline and periodic liver enzyme tests. - Cardiovascular risk evaluation: review history of thromboembolic events. - Drug interaction review: check concomitant medications that may alter letrozole exposure. - Patient counseling: advise on recognizing signs of serious adverse reactions. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Letrozole may interact with other medicines that affect its metabolism or therapeutic effect.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce letrozole exposure. - Estrogen replacement therapy: counteracts aromatase inhibition and diminishes efficacy. - Tamoxifen: antagonistic action may interfere with intended hormonal control.

Moderate Interactions (Monitor Closely): - CYP2C9 inhibitors (e.g., fluconazole): may increase plasma levels, requiring observation. - Warfarin: letrozole can alter anticoagulant effect; monitor INR closely.